Drugs / MTX
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT02066220 | Jun 2014 → Dec 2026 expected | brain cancer | University Medical Center Hamburg-Eppendorf | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MTX | “MTX 2mg intraventricularly, days 1-4, 15, 16, 29, 30, 43-46” NCT02066220 ↗ |
| Route | Other | “MTX 2mg intraventricularly” NCT02066220 ↗ |